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Objective: Although attention deﬁcit
hyperactivity disorder (ADHD) is highly
heritable, genome-wide association studies
(GWAS) have not yet identiﬁed any common
genetic variants that contribute to risk.
There is evidence that aggression or con-
duct disorder in children with ADHD in-
dexes higher genetic loading and clinical
severity. The authors examine whether
common genetic variants considered en
masse as polygenic scores for ADHD are
especially enriched in children with co-
morbid conduct disorder.
Method: Polygenic scores derived from
an ADHD GWAS meta-analysis were cal-
culated in an independent ADHD sam-
ple (452 case subjects, 5,081 comparison
subjects). Multivariate logistic regression
analyses were employed to compare
polygenic scores in the ADHD and com-
parison groups and test for higher scores
in ADHD case subjects with comorbid
conduct disorder relative to comparison
subjects and relative to those without
comorbid conduct disorder. Association
with symptom scores was tested using
linear regression.
Results: Polygenic risk for ADHD, de-
rived from the meta-analysis, was higher
in the independent ADHD group than
in the comparison group. Polygenic score
was signiﬁcantly higher in ADHD case
subjects with conduct disorder relative
to ADHD case subjects without conduct
disorder. ADHD polygenic score showed
signiﬁcant association with comorbid
conduct disorder symptoms. This rela-
tionship was explained by the aggression
items.
Conclusions: Common genetic variation
is relevant to ADHD, especially in indi-
viduals with comorbid aggression. The
ﬁndings suggest that the previously pub-
lished ADHD GWAS meta-analysis contains
weak but true associations with common
variants, support for which falls below
genome-wide signiﬁcance levels. The
ﬁndings also highlight the fact that ag-
gression in ADHD indexes genetic as well
as clinical severity.
(Am J Psychiatry 2013; 170:909–916)
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Attention deﬁcit hyperactivity disorder (ADHD) is
a highly heritable early-onset neurodevelopmental disor-
der, with marked clinical heterogeneity, affecting males
more often than females (1–3). It has a complex genetic
architecture, as is the case for most common psychiatric
disorders. Although associated rare variants have been
identiﬁed (4–7), the general view is that the most satis-
factory explanatory model of inheritance is a multifactorial,
polygenic liability threshold one in which the combined
effects of multiple common genetic variants with environ-
mental factors contribute to ADHD risk.
With respect to common risk variants, there are no
genome-wide signiﬁcant ﬁndings for ADHD (8, 9). Al-
though it has been proposed that this simply reﬂects
inadequate sample sizes (5, 10), others suggest that the
lack of ﬁndings is a consequence of psychiatric disorders
(including ADHD) being explainedmainly or solely by rare
high-penetrance variants (11). So far, for ADHD, rare
variants in the form of copy number variants (CNVs) have
been found to be associated (4–7), and studies have shown
that other classes of rare mutations make some contri-
bution to autism spectrum disorder (ASD) (12–14), an-
other childhood-onset disorder that strongly overlaps with
ADHD (15). While the issue of the relative contributions of
common and rare variants is far from being empirically
resolved, pathway-analytic approaches have shown that
not only do both contribute to ADHD, but they tend to act
on similar functional classes of genes (5, 16).
Given a contribution from both common and rare alleles
(and presumably also alleles with intermediate frequencies),
the multifactorial, polygenic liability threshold model pre-
dicts that forms of the disorder in groups of people less often
affected (e.g., ADHD in females) orwithmore severe forms of
the disorder should carry a greater genetic load, including
greater enrichment of ADHD common risk alleles.
The presence of conduct disorder in youths with ADHD
is known to index greater clinical severity (17). Twin and
family studies have also shown that in children with
ADHD, the presence of conduct disorder symptoms
indexes higher ADHD familial and genetic loading
(18–22). For example, the relative risk for ADHD in bio-
logical relatives of probands who have ADHD with
comorbid conduct disorder (relative risk=9.5) is almost
double that of relatives of probands with ADHD alone
(relative risk=5.4) (18). These studies suggest that in
ADHD, the presence of conduct disorder likely indexes
greater genetic load. Previously, it has only been possible
to infer this indirectly by measuring recurrence rates in
various classes of relatives, but recent developments now
allow the component attributable to relatively common
alleles to be estimated using genome-wide molecular ge-
netic data in the form of polygenic load (23–25). In the
present study, we used ADHD polygenic risk scores de-
rived from the largest published genome-wide association
meta-analysis (8) to test in an independent sample whether
ADHDaccompaniedby conduct disorder is characterized by
greater enrichment of ADHD “risk alleles.” We also in-
vestigated the relationship between polygenic score and
conduct disorder symptoms.
Method
Study Subjects
Participants for what we term in this study the “Cardiff
sample” were recruited from child and adolescent mental health
services or community pediatric outpatient clinics in the United
Kingdom. The sample of 452 children met criteria for a lifetime
DSM-III-R or DSM-IV diagnosis of ADHD, conﬁrmed by a re-
search diagnostic assessment (26). Children with bipolar dis-
order, schizophrenia, ASD, Tourette’s syndrome, an IQ ,70
(assessed using the WISC-III or WISC-IV) (27, 28), epilepsy, or any
other neurological or genetic disorder were excluded. Written
informed consent from parents and assent or consent from
children was obtained for all participants. The study protocol was
approved by North-West England and Wales Multicentre Re-
search Ethics Committees.
The comparison sample comprised 5,081 individuals from the
Wellcome Trust Case Control Consortium–Phase 2.
Clinical Measures
For the Cardiff sample, ADHD diagnoses were conﬁrmed using
the Child and Adolescent Psychiatric Assessment (26), a research
diagnostic interview undertaken with the child’s parents. Inter-
views were conducted by trained psychologists who were
supervised weekly by a child psychiatrist and a psychologist.
Interrater reliability for diagnosis of ADHD subtype, assessed
using 60 cases, was excellent (kappa=1.0). Information on symp-
tom pervasiveness and impairment in school was obtained using
the Child ADHD Teacher Telephone Interview (29) or the DuPaul
(30) or Conners teacher rating scales (31).
The Child and Adolescent Psychiatric Assessment was also
used to assess comorbid psychiatric disorders. Interrater reli-
ability for parent-rated conduct disorder symptoms was very
good (intraclass correlation=0.98). Summed scores for total
number of DSM-IV conduct disorder symptoms were obtained
in addition to diagnoses. In line with previous studies and factor
analyses (32, 33), total counts for aggressive symptoms (DSM-IV
conduct disorder criteria labeled as “aggression to people and
animals”) and covert symptoms (DSM-IV conduct disorder crite-
ria labeled as “destruction of property” or “deceitfulness or theft”)
were generated. (For a full list of DSM-IV aggressive and covert
conduct disorder symptoms, see the data supplement that accom-
panies the online edition of this article.)
Genotyping
DNA was obtained through saliva and blood samples. Ge-
notyping for cases was performed on the Illumina (San Diego)
Human660W-Quad BeadChip. Genotyping for comparison sub-
jects was performed using the Illumina Human 1.2M BeadChip.
The samples, quality control assessment, and genome-wide as-
sociation study results have been described in detail previously (5).
Data Used to Derive ADHD Polygenic Risk Scores
We used the international meta-analysis of ADHD versus
control data, described in detail elsewhere (8). This data set
contains data for 2,064 trios, 896 case subjects, 2,455 comparison
individuals, and 1,206,461 single-nucleotide polymorphisms
(SNPs). Case subjects were assessed with the same inclusion
criteria and by methods similar to those used in the Cardiff study.
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A total of 54 individuals with ADHD were removed from the
Cardiff sample because they had been included in the meta-
analysis (8). The comparison groups did not overlap.
Polygenic Analysis
We used the analytic approach described by the International
Schizophrenia Consortium (25) with the published meta-analysis
of ADHD (8) as the discovery data set and Cardiff sample ADHD
data as the target set. Each individual in the target set was
assigned a polygenic score based on information in the discovery
set. We made comparisons between ADHD case subjects (with
and without conduct disorder) and comparison subjects to
determine whether the ADHD-derived polygenic scores were
signiﬁcantly different. As comorbid conduct disorder indexes
higher ADHD familial loading, our key aim was to test whether
polygenic scores for ADHD were higher in ADHD case subjects
with conduct disorder compared to those without.
We ﬁrst selected a set of SNPs in relative linkage equilibrium in
our ADHD and comparison samples using a sliding window of
200 SNPs, moving it along the genome in steps of ﬁve SNPs and
dropping a SNP when the pairwise estimate of linkage disequi-
librium (r2) was greater than 0.2 (PLINK command:–indep-
pairwise 200 5 0.2) (34). In the discovery meta-analysis data set,
we identiﬁed corresponding p values and associated alleles for
the selected SNPs. Based on the ﬁndings from the International
Schizophrenia Consortium (25) and Psychiatric Genetics Con-
sortium studies (23, 24), which identiﬁed a relaxed p value ,0.5
as the optimal “association” threshold in discovery samples of
the size equivalent to those used here, we deﬁned this a priori as
the threshold from which to derive score alleles from our
discovery sample. Alleles that are more common in the discovery
cases at p,0.5 for two-tailed p values are termed the “score”
alleles (34). For each individual in the target sample, we used
PLINK to obtain a polygenic score that corresponds to the mean
number of score alleles across the set of SNPs. We employed
logistic regression analysis to compare the polygenic scores for
ADHD in the target set to those in the comparison sample. To
allow for population stratiﬁcation in our data, we conditioned on
two covariates (the ﬁrst two principal components estimated
from our GWAS data using the EIGENSTRAT software package,
which was designed for this purpose (35, 36). We hypothesized
a priori that ADHD “risk alleles” derived from the published
GWAS would be enriched in our independent ADHD sample
(relative to the comparison sample), and in particular in those
with conduct disorder. Therefore, for each analysis, we report
a one-tailed p value and pseudo-R2, the latter being a measure of
the estimated variability in case-control status explained.
Using logistic regression analysis, we then compared polygenic
score in those with and without a conduct disorder diagnosis
from the set of ADHD cases (ADHD with conduct disorder com-
pared with ADHD without conduct disorder).
Linear regression analyses were used to investigate whether
polygenic score was signiﬁcantly associated with total DSM-IV
conduct disorder symptom score, as well as aggression and
covert conduct disorder symptom scores. Our rationale for
further dividing conduct disorder symptoms into two subgroups
was based on factor analyses (33) showing that they can be split
into aggressive symptoms (such as cruelty to people or animals,
ﬁghting, and stealing with confrontation of the victim) and covert
symptoms (such as ﬁre-setting, breaking into a building or car,
and vandalism).
Results
A total of 452 children from the Cardiff sample met
inclusion criteria and had genetic and phenotypic data
available. They ranged in age from 6 to 17 years (mean=10.7
years, SD=2.8); 389 were male (86.1%) and 63 were female
(13.9%). The mean full-scale IQ was 87 (SD=11.2). The
gender ratio and IQ scores are typical of U.K. ADHD clinic
case subjects. The mean number of ADHD symptoms was
14.68 (SD=2.87; 25th percentile ADHD score=13.00, 50th
percentile=15.00, 75th percentile=17.00). Within this sam-
ple, 77 individuals (17.0%) had a diagnosis of ADHD with
conduct disorder and 375 (83.0%) had no comorbid
conduct disorder. The mean numbers of DSM-IV conduct
disorder symptomswere 3.6 (SD=1.86) and 0.5 (SD=0.76) for
the ADHD groups with and without conduct disorder,
respectively. There was no association between conduct
disorder scores, age, and gender. In addition, 229 (50.7%)
subjects met criteria for a DSM-IV diagnosis of oppositional
deﬁant disorder; 65 of those with a conduct disorder
diagnosis (84.4%) also had a diagnosis of oppositional
deﬁant disorder. Twenty-two individuals (4.9%) had a
comorbid diagnosis of anxiety disorder, and three in-
dividuals (0.7%) had a comorbid depressive disorder.
Polygenic Scores Predicting ADHD in the Target
Sample
ADHD risk as deﬁned from weakly associated alleles
(N=46,156) in the discovery GWAS was signiﬁcantly higher
in ADHD case subjects than in comparison subjects
(p=0.01) (Table 1). Thus, as we postulated, risk for ADHD
is in part attributable to common alleles tagged by the
genome-wide genotyping arrays.
Polygenic Score Enrichment in Those With ADHD
Accompanied by Conduct Disorder
The polygenic score representing ADHD risk was
signiﬁcantly higher in ADHD case subjects who had
a conduct disorder diagnosis than in those who did not
(p=0.01). The magnitude of the effect (as deﬁned by R2)
was 1.1%, larger than that observed when comparing
ADHD case subjects and comparison subjects (Table 1).
To test whether our ﬁndings could be attributable to
higher ADHD total symptom counts in those with conduct
disorder, we tested the association between ADHD symp-
tom count and polygenic risk score. Within ADHD case
subjects, the total number of ADHD symptoms was not
signiﬁcantly associated with polygenic score. As expected,
total ADHD score was signiﬁcantly associated with total
conduct disorder score (b=0.159, t=22.900, p=0.004).
ADHD polygenic risk scores were signiﬁcantly higher in
female than in male case subjects (b=20.104, t=22.159,
p=0.031), and hence all the data were reanalyzed allowing
for sex as a covariate. The results were unchanged (data
not shown).
Polygenic Score Predicting Conduct Disorder
Symptom Scores
Within case subjects, ADHD polygenic risk score in-
creased with total conduct disorder score (b=0.118, t=2.530,
p=0.006). At the level of individual composite phenotypes,
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polygenic risk score also increased with number of
aggressive conduct disorder symptoms (b=0.151, t=3.152,
p=0.002), but not covert conduct disorder symptoms.
These associations remained signiﬁcant when controlling
for sex. The distribution of risk scores showed increasing
polygenic score with respect to increasing total conduct
disorder scores (Figure 1).
Discussion
We initiated this study to investigate the contribution of
common genetic variants to ADHD and to test whether
comorbid conduct disorder, deﬁned categorically and
dimensionally, indexed greater genetic risk at a molecular
level. Our data support a polygenic component to ADHD,
in that the risk score was higher in our independent
sample of ADHD case subjects than in the comparison
sample. To our knowledge, this is the ﬁrst report to suggest
that the previously published ADHD GWAS meta-analysis
(8) harbors common risk alleles that show contribution to
ADHD when they are considered en masse. More impor-
tantly, as hypothesized on the basis of previous family and
twin studies suggesting that comorbid conduct disorder
indexes higher familial and genetic loading in ADHD, we
found that ADHD risk score is particularly elevated in
those with ADHD and conduct disorder compared with
those who have ADHD only.
A within-case analysis of conduct disorder symptoms as a
dimension rather than a category revealed similar ﬁndings,
with a positive linear relationship between ADHD polygen-
ic scores and comorbid conduct disorder symptoms. In-
terestingly, this association was related to aggressive, rather
than covert, conduct disorder symptoms. Twin studies also
suggest that these different symptom dimensionsmay be
distinct in their genetic etiology, with stronger genetic
loading for overt aggressive symptoms (32, 37).
Overall, our study conﬁrms the hypothesis that com-
mon genetic variants are relevant to ADHD risk. Our
ﬁndings also highlight the fact that comorbid conduct
disorder indexes heterogeneity in terms of genetic loading
at a molecular level. Our ﬁnding that individual symptom
groups of total conduct disorder scores and aggressive
conduct disorder scores are signiﬁcantly associated with
polygenic score further underscore the point that speciﬁc
clinical phenotypes can index differential genetic loading.
Most of the evidence to date suggests that conduct
problems index ADHD cases that are quantitatively rather
than qualitatively different from the remaining ADHD
cases (38) in terms of the patterns of association with
clinical, cognitive, genetic, and environmental correlates.
This is in keeping with the approach taken by ICD-10, in
which hyperkinetic conduct disorder is considered a sub-
type of ADHD/hyperkinetic disorder (39). However, some
associated factors also appear to be unique to conduct
disorder in ADHD. Notably, the functional COMT Val158-
Met variant has been found to be associated with conduct
problems in ADHD (40), a ﬁnding that has been replicated
in six independent samples (32, 41–43), while meta-
analysis shows that this variant is not associated with
ADHD risk (44). A separate issue of interest would be
to investigate the independent contribution of genetic
liability associated with conduct disorder (regardless of
ADHD). There is evidence to suggest shared liabilities, but
as yet, large-scale conduct disorder GWAS data sets are
unavailable.
TABLE 1. Summary of Results Using the Published ADHD Meta-Analysis as the Discovery Data and the Cardiff Data Set as the
Target Samplea
Comparison Analysis (Sample 1 Versus Sample 2)
Sample sizes z R2 (%) pSample 1 Sample 2
Total ADHD sample Comparison group 452 and 5,081 2.32 0.098 0.010
ADHD with conduct disorder Comparison group 77 and 5,081 3.11 0.190 0.00095
ADHD, no conduct disorder Comparison group 375 and 5,081 1.27 0.030 0.10
ADHD with conduct disorder ADHD, no conduct disorder 77 and 375 2.23 1.1 0.013
a Meta-analysis data are from reference 8. In all analyses, the ADHD case subjects had more risk alleles than the comparison subjects. All
z statistics are distributed with one degree of freedom, and all p values are one-tailed.
FIGURE 1. Distribution of Polygenic Scores for ADHD, by
Total Conduct Disorder Scorea
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a The whiskers extend to the most extreme data point, which is no
more than 1.5 times the interquartile range from the box. The
horizontal bars indicate median scores, and the blue dots
represent outliers.
912 ajp.psychiatryonline.org Am J Psychiatry 170:8, August 2013
HIGH LOADING OF POLYGENIC RISK FOR ADHD IN CHILDREN WITH COMORBID AGGRESSION
We also incidentally found that female case subjects
had signiﬁcantly higher ADHD risk scores than males.
This ﬁnding requires replication, but it is intriguing, as
it supports the hypothesis that ADHD is less common in
females because a more extreme genetic load is required
for the liability threshold to be surpassed. This would
predict that relatives of female ADHD probands have
a greater risk for ADHD than relatives of male ADHD
probands, although evidence here is lacking (3). However,
there is a possible effect of ascertainment bias. Females
with ADHDmay be less likely to be diagnosed (or referred
for diagnosis) than males with comparable severity of
disorder (45), and therefore our ﬁndings might simply
reﬂect a higher threshold of severity for females to be
diagnosed and ascertained. However, females in our
sample did not have signiﬁcantly more ADHD or conduct
disorder symptoms than males.
As expected, ADHD severity (i.e., total ADHD score)
showed association with conduct disorder scores, but the
genetic ﬁndings were driven by conduct disorder, as there
was no association between ADHD severity and polygenic
risk. Given that all clinical case subjects have high ADHD
scores by deﬁnition, and thus variance is limited, this may
not be surprising.
It is noteworthy that case-control comparisons were
signiﬁcant for the total ADHD group and for the ADHD
with conduct disorder group but did not achieve signiﬁ-
cance in the ADHD without conduct disorder group. This
result might simply reﬂect sample size, whereby larger
samples would be needed to demonstrate statistically
signiﬁcant differences in groups with lower genetic load
(those with ADHDwithout conduct disorder) than in those
with higher genetic load (those with ADHD with conduct
disorder).
This study used a well-characterized sample of children
who underwent careful phenotyping. The diagnosis of
ADHD was conﬁrmed using a semistructured research
diagnostic interview, which also allowed the collection of
detailed information on conduct disorder symptoms, and
the measures showed high reliability. It is not possible to
obtain clinical data on the comparison subjects, although
failure to exclude comparison subjects with ADHD or
conduct disorder would reduce our study’s statistical
power, not generate false positives. One limitation of case-
control and within-case studies is the possibility of
population stratiﬁcation. However, we limited the impact
of stratiﬁcation by the well-accepted approach of in-
cluding derived principal components that allow for
population variation (35, 36) in our ADHD GWAS and by
using hypothesis-driven analyses. Furthermore, for strat-
iﬁcation to be an issue, it would have to be refractory to
inclusion of the principal components, and the same
uncorrected ethnic variation would have to be over-
represented in case subjects in both the Cardiff sample
and the samples used in the meta-analysis (46); it would
also have to be speciﬁcally overrepresented in subjects
with comorbid conduct disorder compared with the full
ADHD sample.
The magnitudes of the polygenic effect (as deﬁned by
R2) are small, as is typical when this method is used. The
magnitudes are also smaller than some of those published
for schizophrenia (R2=3%–6% [24, 25]) but not all (47). This
method is also very sensitive to sample size, and available
GWAS data sets for ADHD are very much smaller than
those for schizophrenia. In the most recent schizophrenia
analysis, with more than 9,000 case subjects and 12,000
comparison individuals (24), the total amount of variance
explained was estimated to be 6%, whereas in an earlier
analysis of 3,000 case subjects and 3,000 comparison
subjects by the International Schizophrenia Consortium
(25), the estimate was 3%. Our estimate that 0.1% of the
variance explained is based on much smaller samples,
with 452 ADHD case subjects and 5,081 comparison
subjects. Another factor that would reduce explained
variance is heterogeneity across samples. This could
plausibly be higher for some disorders than others—for
example, through international differences in clinical
service provision and thus in ascertainment, as well as
other variability, such as ethnic composition. It is also
important to note that GWAS SNP arrays do not com-
pletely capture relevant genetic variation; they “tag” po-
tentially causal variants, and the arrays do not capture the
full spectrum of allelic frequencies or allele types (e.g.,
repeat sequence polymorphisms such as variable number
tandem repeats). Overall, we expect that as more ADHD
and comparison samples with more comprehensive
genetic capture become available, more variance will be
explained. Finally, we also acknowledge the contribution
of environmental risk factors and gene-environment
interplay, although this was not the focus of the present
analyses.
These ﬁndings suggest that ADHD, like other psychiatric
disorders, can be considered a polygenic disorder, the
architecture of which includes common as well as rare
alleles (10). They are also compatible with our earlier work
showing overlap between the biological processes
enriched for weak ADHD SNP association signals and
those enriched for rare copy number variants (5). Given
the evidence for contribution of common variants, the
future acquisition and genetic analysis of much larger
ADHD samples in an attempt to capture relevant genetic
variation is crucial. The aim is not to simply identify single
“signiﬁcant” SNPs of small effect size, but rather to utilize
the spectrum of associated common and rare genetic risk
variants to uncover novel clues for risk mechanisms and
underlying biology and to inform our conceptualization of
ADHD.
In summary, we found that common genetic variation
appears relevant to ADHD and that a higher loading for
common ADHD genetic risk variants is indexed by comor-
bid conduct disorder, especially aggressive symptoms. Our
results also suggest that the previously published ADHD
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GWAS meta-analysis contains weak but true associations
to common variants, support for which falls below cur-
rently accepted genome-wide signiﬁcance levels. The
ﬁndings highlight the fact that aggression in ADHD, as
an index of clinical severity, is underpinned by higher
genetic loading at a molecular level. They also illustrate
that for hypothesis-driven research, careful phenotyping is
still useful in psychiatric genetic studies.
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